445 related articles for article (PubMed ID: 31010834)
1. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer-Derived Exosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms.
Neviani P; Wise PM; Murtadha M; Liu CW; Wu CH; Jong AY; Seeger RC; Fabbri M
Cancer Res; 2019 Mar; 79(6):1151-1164. PubMed ID: 30541743
[TBL] [Abstract][Full Text] [Related]
3. Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors.
Veneziani I; Infante P; Ferretti E; Melaiu O; Battistelli C; Lucarini V; Compagnone M; Nicoletti C; Castellano A; Petrini S; Ognibene M; Pezzolo A; Di Marcotullio L; Bei R; Moretta L; Pistoia V; Fruci D; Barnaba V; Locatelli F; Cifaldi L
Cancer Immunol Res; 2021 Feb; 9(2):170-183. PubMed ID: 33303573
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.
Xu Y; Sun J; Sheard MA; Tran HC; Wan Z; Liu WY; Asgharzadeh S; Sposto R; Wu HW; Seeger RC
Cancer Immunol Immunother; 2013 Oct; 62(10):1637-48. PubMed ID: 23982484
[TBL] [Abstract][Full Text] [Related]
5. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
7. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
[TBL] [Abstract][Full Text] [Related]
8. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
9. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Cancer Immunotherapy with Smad3-Silenced NK-92 Cells.
Wang QM; Tang PM; Lian GY; Li C; Li J; Huang XR; To KF; Lan HY
Cancer Immunol Res; 2018 Aug; 6(8):965-977. PubMed ID: 29915022
[TBL] [Abstract][Full Text] [Related]
11. Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.
Witham TF; Villa L; Yang T; Pollack IF; Okada H; Robbins PD; Chambers WH
J Neurooncol; 2003; 64(1-2):63-9. PubMed ID: 12952287
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.
Ng S; Deng J; Chinnadurai R; Yuan S; Pennati A; Galipeau J
Cancer Res; 2016 Oct; 76(19):5683-5695. PubMed ID: 27488533
[TBL] [Abstract][Full Text] [Related]
13. Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma in vitro and in vivo.
Pérez-Martínez A; Valentín J; Fernández L; Hernández-Jiménez E; López-Collazo E; Zerbes P; Schwörer E; Nuñéz F; Martín IG; Sallis H; Díaz MÁ; Handgretinger R; Pfeiffer MM
Cytotherapy; 2015 May; 17(5):601-12. PubMed ID: 25541298
[TBL] [Abstract][Full Text] [Related]
14. Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization.
Powell AB; Yadavilli S; Saunders D; Van Pelt S; Chorvinsky E; Burga RA; Albihani S; Hanley PJ; Xu Z; Pei Y; Yvon ES; Hwang EI; Bollard CM; Nazarian J; Cruz CRY
J Transl Med; 2019 Sep; 17(1):321. PubMed ID: 31547819
[TBL] [Abstract][Full Text] [Related]
15. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
16. Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.
Dasgupta A; Shields JE; Spencer HT
Hum Gene Ther; 2012 Jul; 23(7):711-21. PubMed ID: 22397715
[TBL] [Abstract][Full Text] [Related]
17. Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment.
Wu D; Kuiaste I; Moreau P; Carosella E; Yotnda P
Oncotarget; 2015 Nov; 6(35):37385-97. PubMed ID: 26460949
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
[TBL] [Abstract][Full Text] [Related]
19. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
20. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
